You are here: Industry Insights > patients

News List

New cholesterol-lowering drug could help patients unable to take statins worldpharmanews
March 14, 2019
A new class of oral cholesterol-lowering drug could help patients unable to take statins due to side effects.
AstraZeneca, Seres in Cancer Research Tie-up contractpharma
March 13, 2019
Seres to receive $20 million and financial support for research activities
La Jolla Pharmaceutical Appoints CCO contractpharma
March 12, 2019
Darryl Wellinghoff has had 19 years experience in the pharmaceutical industry including 15 years at The Medicines Company.
Boston agency projects photos of patients onto City Hall as Rare Disease Day reminder fiercepharma
March 03, 2019
Patients’ faces will light up Boston City Hall Thursday night as part of one Boston agency’s annual Rare Disease Day campaign.
Wuxi Biologics Begins Construction of Facility in Ireland contractpharma
December 27, 2018
WuXi Biologics has begun the construction of new biologics drug substance manufacturing facility in Ireland on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth.
Selexis, Teneobio Enter Second Services Agreement contractpharma
December 21, 2018
Selexis SA and Teneobio, Inc. have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics. Teneobio will utilize Selexis’ SUREtechnology Platform
Recipharm to Potentially End Operations in UK Site contractpharma
December 21, 2018
Recipharm has announced it is considering the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK.
FDA Grants Mustang Bio ODD contractpharma
December 21, 2018
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mustang Bio’s MB-102 (CD123 CAR T) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Ajinomoto, XL-protein Forge Strategic Alliance contractpharma
December 19, 2018
Ajinomoto Bio-Pharma Services and XL-protein GmbH, a German biopharmaceutical company, have entered a Strategic Alliance, under which Ajinomoto will apply its Corynex expression system
Neurotrope Announces Publication of Phase 2 Alzheimer's Study contractpharma
December 18, 2018
Neurotrope Inc. announced that data from its Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease were published online in the Journal of Alzheimer's Disease.

Previous page 1 2 3 4 5 6 7 8 Next page